Methods for treatment of diabetes using peptide analogues of insulin
AssigneeNeurocrine Biosciences, Inc.
InventorsAmitabh Gaur, Nicholas Ling, Paul J. Conlon
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues arc provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.
Claims18
A peptide analogue comprising amino acid residues 9 to 23 of human insulin B chain wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to amino acid alanine substitutions of 1, 2, 3 or 4 amino acid residues within the residues 9 to 23 of human insulin B chain, wherein at least one substitution occurs at a residue selected from the group consisting of residues 12, 13, 15 and 16 of SEQ ID NO:1, wherein the peptide analogue comprises no more than 18 residues of human insulin B chain, and wherein the peptide analogue is capable of reducing incidence of diabetes in non-obese diabetic (NOD) mice.
A peptide analogue comprising amino acid residues 9 to 23 of human insulin B chain, wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to amino acid substitutions at residues 16 and 19 of SEQ ID NO:1, wherein said substitutions comprise L or D-amino acids.
Dependencies are inferred from the claim text.